Berobenatide Blackstone funding gives Pfizer up to 1.5 billion dollars for monthly GLP 1 trials
Blackstone Life Sciences will cover up to 1.5 billion dollars of berobenatide development costs through 2028 in return for milestones tied to US approval and sales, with no rights in the drug.
What's new
Blackstone Life Sciences agreed to fund up to 1.5 billion dollars of development costs for Pfizer's monthly GLP 1 peptide berobenatide through 2028, in return for milestone payments.
Why it matters
The deal pays for a large Phase 3 program after Pfizer's 10 billion dollar Metsera purchase, while Pfizer keeps all rights and control of the drug.
What's next
Ten Phase 3 trials are ongoing or planned. Blackstone is paid only if monthly berobenatide wins US approval for weight management and hits sales targets.
Berobenatide Blackstone funding of up to 1.5 billion dollars will pay for part of the late stage program behind Pfizer's monthly GLP 1 injection, the two companies said on November 11. Funds managed by Blackstone Life Sciences will cover development costs for the peptide through 2028. In return, Blackstone can earn milestone payments if the drug wins United States approval and reaches certain sales levels, but it takes no ownership of the medicine. Pfizer keeps full control of the program and every decision about its trials.
What the berobenatide Blackstone funding covers
According to the Pfizer release, the money supports development of berobenatide, also known as PF'3944, an investigational GLP 1 receptor agonist peptide designed to be injected once a month. Pfizer is testing it for chronic weight management and for conditions linked to obesity, including knee osteoarthritis and obstructive sleep apnea. The company lists ten Phase 3 studies of the drug that are ongoing or planned, and says its wider obesity effort could pass 20 trials in 2026. Pfizer also plans to test berobenatide on its own and in combination with other gut hormone peptides, including amylin analogs. The release does not name the individual trials, give enrollment numbers or set out dates for results.
The structure matters. Blackstone does not buy a share of future sales or any rights to the drug. It pays a portion of the costs now and is eligible for milestone payments tied to United States approval of monthly berobenatide used alone for chronic weight management, and to certain sales targets, with any payments spread over several years. Neither company disclosed the size of those milestones. Funds from Blackstone's perpetual private equity strategy will invest alongside its life sciences funds. Pfizer chief financial officer Cecile Guegan said the deal helps the company "maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas". Blackstone said it has 18 billion dollars under management in life sciences.
Why Pfizer wants a monthly GLP 1 injection
Pfizer came to berobenatide through its purchase of Metsera, where the drug carried the code MET-097. BioPharma Dive reports that Pfizer first offered 4.9 billion dollars for Metsera, was drawn into a bidding contest with Novo Nordisk and won with an offer of 10 billion dollars in November 2025. The purchase followed Pfizer's decision to drop several of its own oral obesity candidates over safety problems. Since then, both Novo and Eli Lilly have brought weight loss pills to market, so Pfizer has bet on an injection that lasts longer than the weekly shots Wegovy and Zepbound. A monthly schedule could suit people who find weekly injections a burden.
A monthly schedule could suit people who find weekly injections a burden.
Pfizer is not alone in chasing longer dosing intervals. Camurus has started a Phase 2b trial of a monthly semaglutide depot, and several groups are working on amylin based drugs that could be paired with GLP 1 agonists. Efficacy still decides the market, though. Lilly is pressing ahead with retatrutide, a triple agonist that has produced larger average weight loss than current drugs in its trials, while Pfizer is betting that convenience and combination options will win patients and prescribers. Whether a monthly peptide can match weekly drugs on weight loss and tolerability will only be clear once the Phase 3 results arrive. The terms are set out in the Pfizer and Blackstone release.
Obesity trial costs and private capital
Obesity trials are large and slow. BioPharma Dive notes that Foundayo, the newest weight loss drug approved in the United States, was tested in about 4,700 people across its two pivotal obesity trials, each with a 72 week evaluation period. Pfizer may also want head to head trials against Zepbound or Wegovy to set its drug apart, which would add cost. Sharing that burden with an outside investor, as the berobenatide Blackstone funding does, lets a drugmaker keep spending on other programs while it waits for the obesity data. For an investor, milestone deals offer a return without the work of running trials. The approach has spread across the industry as pivotal programs grow bigger and the bar for new obesity drugs keeps rising.
Blackstone has used this model before. BioPharma Dive lists earlier commitments of up to 2 billion dollars with Alnylam Pharmaceuticals in cardiovascular disease, 750 million dollars for Moderna's flu vaccine work, 700 million dollars behind a Merck cancer drug and 400 million dollars for a gut disease drug from Teva and Sanofi. MedCity News adds a deal of up to 1.3 billion dollars with Apogee Therapeutics, which carried royalties rather than milestones. Readers can compare this with other recent ways of paying for GLP 1 development, such as the Corxel SPAC deal for an oral candidate. The table below sets out the main terms of the Pfizer agreement as disclosed so far.
| Deal term | What was disclosed |
|---|---|
| Announced | 11 November 2026 |
| Funding | Up to 1.5 billion dollars of development costs through 2028 |
| Drug | Berobenatide, monthly GLP 1 receptor agonist peptide |
| Return to Blackstone | Milestones tied to US approval and sales targets |
| Rights or ownership | None for Blackstone, Pfizer keeps full control |
| Phase 3 program | Ten trials ongoing or planned |
What remains unknown about the monthly GLP 1
Key details are missing. Neither company has given the value of the milestone payments, the share of total program costs that Blackstone will cover or the timing of the first Phase 3 readouts. The release also leaves out efficacy figures, so readers must rely on earlier published Phase 2 data, which this story does not restate. Berobenatide is an investigational drug. It is not approved anywhere, and no regulator has reviewed its safety or effectiveness for long term use. Any statement about when it could reach patients is a company plan rather than a fact. Phase 3 trials in obesity commonly run for more than a year before results, so the clearest test of the deal will come later.
For Pfizer, the deal is a way to keep a broad obesity program moving after a costly acquisition, without carrying the full bill alone. For Blackstone, it is a wager that monthly dosing will earn United States approval and sell well enough to trigger payments. Both outcomes depend on trial data that do not yet exist. The key questions for the Phase 3 program are whether monthly dosing holds weight loss steady between injections, how often digestive side effects lead people to stop, and how the drug compares with weekly options in direct tests. Coverage of deals and funding across the peptide sector continues on the Peptide Zone industry desk.
Conclusion
The berobenatide Blackstone funding gives Pfizer up to 1.5 billion dollars for a large Phase 3 program while leaving all rights with Pfizer. Blackstone is paid only if monthly berobenatide wins United States approval and meets sales goals. The deal says nothing new about how well the drug works. That answer will come from the ten Phase 3 trials, and until then the monthly GLP 1 remains an unproven bet on convenience.